ORG
Merus Phase 2 Data: Analysts See Strong Survival in Head & Neck Cancer, ‘Home Run’ Hopes Emerge
Merus; petosemtamab; Phase 2; overall survival; head and neck cancer; Pembrolizumab; Keytruda; clinical trial; analyst reaction; home run scenario
Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025
Jazz Pharmaceuticals; Zepzelca; lurbinectedin; lung cancer; small cell lung cancer; Tecentriq; atezolizumab; IMforte trial; overall survival; progression-free survival; ASCO 2025
Will Trump’s Tax Bill Cut Medicare by $490 Billion? Not Exactly.
Trump tax bill; Medicare cuts; sequestration; budget reconciliation; 2025 healthcare changes; CBO report
Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline
Sanofi; Vigil Neuroscience; acquisition; Alzheimer’s disease; TREM2 agonist; VG-3927; microglia; neurodegenerative disease; Phase 2 trials; biotech deals
HHS: All Branded Drugs Without Generic or Biosimilar Competition Must Abide by MFN Order Across All Markets
most-favored nation pricing; branded drugs; generic competition; biosimilar competition; HHS; executive order; drug pricing; pharmaceutical industry; OECD countries
FDA Expects ‘Timely Availability’ of Covid Shots as Advisors Update Formula Recommendation
FDA; Covid-19; vaccine; formula update; timely availability; advisory committee; JN.1-lineage; KP.2 strain; 2025-2026
Post-Hoc: AI bio needs to heed the overhyped history of CRISPR
CRISPR; AI in biotech; overhype; gene editing; reproductive health biotech
FDA Advisory Committee Unanimously Votes Against Expanding Pfizer’s Prostate Cancer Drug Combo
FDA; advisory committee; Pfizer; Talzenna; talazoparib; enzalutamide; prostate cancer; mCRPC; PARP inhibitor; label expansion; unanimous vote
Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application
Moderna; mRNA-1083; combination vaccine; flu; COVID-19; FDA; Biologics License Application; vaccine efficacy; clinical trial; share price
FDA Advisory Committee Narrowly Votes Against UroGen’s Bladder Cancer Drug, Calls for Further Studies
FDA; UroGen Pharma; UGN-102; bladder cancer; Oncologic Drugs Advisory Committee; mitomycin; RCT; non–muscle invasive bladder cancer; clinical trials